REG - AOTI, Inc. - Grant of performance share awards under LTIP

AotiAnnouncement

17/12/2024 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241217:nRSQ4367Qa&default-theme=true

RNS Number : 4367Q  AOTI, Inc.  17 December 2024

17 December 2024

 

 

AOTI, INC. (the "Company" or "Group" or "AOTI")

 

Grant of performance share awards to CFO under Long Term Incentive Plan

 

AOTI, INC., a medical technology group focused on the durable healing of
wounds and prevention of amputations, announces that on 17th December 2024,
the Company granted awards over ordinary shares in the form of nominal cost
options (Performance Awards) under the AOTI Long Term Incentive Plan (LTIP) to
Jayesh Pankhania, CFO, who joined AOTI in June 2024 and is a Person
Discharging Managerial Responsibilities (PDMR), as detailed below:

 

 PDMR              Role                     Number of Performance Awards  Exercise Price ($)
 Jayesh Pankhania  Chief Financial Officer  208,333                       0.00001

 

In determining the number of awards, the Company has used a share price of
132p, being the IPO price.

 

The Performance Awards will vest three years from the grant date conditional
on meeting three-year performance conditions as described below.

 

40% of an award is subject to a revenue growth performance condition measured
over a three-year period ending 31 December 2026.

 

30% of an award is subject to a relative total shareholder return (TSR)
performance condition measured over three years from the date of the IPO.
AOTI's TSR performance will be measured against a sector peer group of UK, US
and other internationally quoted companies with 25% of this portion of the
award vesting at median performance rising on a straight line to full vesting
at upper quartile performance.

 

30% of an award is subject to an absolute total shareholder return performance
condition measured over three years from the date of the IPO. Vesting will
commence from zero at 10% compound annual growth rising on a straight line to
full vesting at 20% compound annual growth.

 

END

 

 AOTI, INC.

 Dr. Mike Griffiths, Chief Executive Officer   +44 (0)20 3727 1000

 Jayesh Pankhania, Chief Financial Officer     ir@aotinc.net (mailto:ir@aotinc.net)

 Peel Hunt LLP (Nominated Adviser and Broker)

 Dr. Christopher Golden, Patrick Birkholm      +44 (0)20 7418 8900

 FTI Consulting (Financial PR & IR)

 Ben Atwell, Simon Conway,                     +44 (0)20 3727 1000

 Natalie Garland-Collins, Alex Davis           AOTI@fitconsulting.com (mailto:AOTI@fitconsulting.com)

 

 

ABOUT AOTI, INC.

 

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and
Galway, Ireland, providing innovative solutions to resolve severe and chronic
wounds worldwide. Its products reduce healthcare costs and improve the quality
of life for patients with these debilitating conditions. The Company's
patented non-invasive Topical Wound Oxygen (TWO(2)(®)) therapy has
demonstrated in differentiating, robust, double-blinded randomised controlled
trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the
recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88
per cent reduction in hospitalisations and 71 per cent reduction in
amputations over 12 months. TWO(2)(®) therapy can be administered by the
patient at home, improving access to care and enhancing treatment compliance.
TWO(2)(®) therapy has received regulatory clearance from the US (FDA), Europe
(CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products
Administration, Australia (TGA) and in Saudi Arabia. Also see www.aotinc.net
(http://www.aotinc.net)

 

 1.  Details of the person discharging managerial responsibilities/person closely
     associated
 a)   Name                                    Jayesh Pankhania
 2.  Reason for the notification
 a)  Position/status                          Chief Financial Officer
 b)  Initial notification/Amendment           Initial Notification
 3.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     AOTI, INC.
 b)  LEI                                      213800ZGCNDSTWIRK687
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares
 b)  Identification code                      US03690C1027
 c)  Nature of the transactions               Initial award under the AOTI LTIP
 d)  Price(s) and volume(s)                   Exercise Price: 0p per share

                                              Volume: 208,333
 e)  Aggregated information                   As for d) above

     - Aggregated volume

     - Price
 f)  Date of the transactions                 17 December 2024
 f)  Place of the transactions                Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFSLFELDLIS